Complete Transparency: Recent FDA Decisions Renew Calls For Making Complete Response Letters Public

Three major stakeholders in drug development—regulators, industry, and investors—say they want or could live with FDA complete response letters being made public. Why aren’t they, and will it happen in the current political environment?